RXi Pharmaceuticals

11.04.2018 | NASDAQ

A New York-based ZAG-S&W Team advised H.C. Wainwright as underwriter, in the $4.9 million offering of common stock and warrants by RXi Pharmaceuticals (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics

Oded Har-Even and Rob Condon advised H.C. Wainwright.

 

 

 

Recent Activity